Summary
Vertex Pharmaceuticals Incorporated (VRTX) filed an 8-K on May 29, 2012, to report a significant event that occurred on May 24, 2012. The primary focus of this filing is the election of Dr. David Altshuler to the company's Board of Directors. Dr. Altshuler has been appointed as a Class II Director, with his term set to conclude at the 2015 annual shareholder meeting. The company has affirmed that Dr. Altshuler meets the independence criteria set forth by the SEC and NASDAQ, making him an independent director.
Key Highlights
- 1Vertex Pharmaceuticals announced the appointment of Dr. David Altshuler to its Board of Directors on May 24, 2012.
- 2Dr. Altshuler's term as a Class II Director will extend until the 2015 annual shareholder meeting.
- 3The company has confirmed Dr. Altshuler's status as an independent director.
- 4Dr. Altshuler brings extensive expertise in genetics and medicine, holding leadership positions at the Broad Institute and Harvard Medical School.
- 5His academic and research background includes a B.S. from MIT, a Ph.D. from Harvard University, and an M.D. from Harvard Medical School.
- 6Dr. Altshuler's appointment may signal a continued focus on scientific innovation and genetic research within Vertex Pharmaceuticals.